Truist reiterates Waystar stock rating on strong bookings growth

Waystar reported Q3 2026 revenue of $325.6 million, up 21% year over year, and adjusted EBITDA of $139 million, up 24%, with non-GAAP diluted EPS of $0.44; AI-powered offerings accounted for 43% of bookings. The company raised full-year adjusted EBITDA guidance but lowered its Q4 revenue-growth outlook, and shares fell 7.4% in after-hours trading amid concerns about slower bookings conversion. Truist reiterated Buy with a $33 price target; management cited 10% organic Q3 revenue growth, a 43% adjusted EBITDA margin, and an Iodine pipeline exceeding $100 million.

Analysis

The key issue is conversion, not demand: bookings and backlog can support future growth, but they do not establish when revenue or cash arrives. Longer implementations and outcome-based pricing make the timing gap especially relevant for Iodine; a larger backlog may also require implementation capacity before it becomes billable. If AI-led bookings convert without diluting economics, Waystar can extend growth while leveraging its reported EBITDA margin. If conversion slips again, the same backlog risks becoming a source of estimate resets rather than a near-term catalyst.

Near term, the post-results selloff despite higher EBITDA guidance suggests the market is prioritizing softer revenue visibility. That tension matters after a substantial six-month share-price run and against an already bullish analyst backdrop: upside may require execution, while disappointments can trigger multiple compression. Over 1–3 months, track quarterly revenue conversion, implementation throughput, and whether management stabilizes the fourth-quarter outlook. Over 6–18 months, sustained AI-product adoption and Iodine deployments could improve the growth profile, but bookings share and pipeline claims need validation in recognized revenue and cash generation.

Contrarian angle: the delayed product rollout and slower conversion may be timing rather than demand impairment, particularly given the returning client and reported pipeline. But the article provides no cohort conversion, customer concentration, or cash-flow detail to underwrite that interpretation. A renewed revenue-guidance cut, backlog growth without corresponding revenue conversion, or weakening EBITDA guidance would falsify the benign-timing thesis.

Key Decisions for Investors

• Do not chase the bullish analyst narrative or automatically buy the post-results weakness. For new exposure, wait for price stabilization and the next evidence of bookings-to-revenue conversion; the present setup has asymmetric disappointment risk after the prior run.
• For existing WAY exposure, keep position sizing tied to revenue visibility rather than bookings growth alone. Reassess on the next report: revenue versus guidance, implementation throughput, Iodine conversion, and operating cash flow are the key checks.
• Set an alert for another revenue-growth reduction or backlog expansion accompanied by weak revenue conversion; that combination would strengthen a trim/underweight case. Conversely, revenue delivery near guidance alongside continued EBITDA guidance support would reduce the timing-risk thesis and justify reconsidering exposure.
• No options trade is warranted from the supplied information: implied volatility, option pricing, and a reliable near-term catalyst calendar are absent.